RxDoctor Payments Data

Ethan Tolbert, MD

Hematology & Oncology · Atlanta, GANPI 1255537239

Payments from drug & device makers

$54,494in general payments, 2019–2025

Across 123 payments — averaging $443.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$9K
  • Pfizer$7K
  • Bayer$5K
  • GSK$5K
  • Sanofi$4K
  • Taiho Oncology, Inc.$4K
  • plus $20K from 23 others

What the payments were for

  • Consulting fees$48,06988%
  • Speaking & faculty fees$1,2002%
  • Travel & lodging$2,4755%
  • Food & beverage$2,5595%
  • Education$1910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,494 in reported general payments places this provider in the 70th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$42,196
Medicare patients
187
Services billed
553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide56$955,803
Lenalidomide43$626,499
ErleadaApalutamide12$172,648
EliquisApixaban23$21,184
XareltoRivaroxaban14$16,183
Fentanyl36$3,132
Oxycodone Hcl140$2,514
Gabapentin67$988
Ibandronate Sodium42$888
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen25$646
Hydroxyurea21$535
Dexamethasone21$404
Prochlorperazine Maleate14$343
Omeprazole11$322
Bupropion Hcl SrBupropion Hcl14$317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$8,595$955,80356 claims
Johnson & JohnsonErleada, Xarelto$4,103$188,83126 claims
PfizerEliquis$6,696$21,18423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →